http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이주찬,서기석,구정회,방경식,한현수,박성원 대한방사선 방어학회 2001 방사선방어학회지 Vol.26 No.1
특수형 방사성물질 운반캡슐은 국내외의 수송관련 법규에 규정된 기술기준을 만족하도록 설계, 제작되어야 한다. 본 연구의 목적은 하나로에서 생산된 192Ir 특수형 동위원소 운반캡슐의 건전성을 평가하는데 있다. 법규에서 규정된 낙하시험, 타격시험, 굽힘시헝 및 가열시험조건에 대한 안전성 시험을 수행하였으며, 각각의 시험 전후에 누설시험을 수행하였다. 또한, 안전성시험과 더불어 컴퓨터코드를 이용한 전산해석을 수행하여 안전성시험 전에 시험결과에 대한 예측자료로 활용되었다. 낙하시험 및 가열시험 결과 캡슐 표면에서 약간의 흠집과 변형이 발생하였으나, 각각의 시험에서 평가기준이 되는 캡슐의 손상이나 용융 등은 발생하지 않았다. 또한 각 시험 후 수행한 누설시험 결과 누설이 발생하지 않았다. 따라서 특수형 방사성물질 운반캡슐은 법규에서 규정하는 기술기준을 만족하도록 설계, 제작되었음이 입증되었다. All of sealing capsules to transport a special form radioactive material should be designed and fabricated in accordance with the design criteria prescribed in IAEA standards and domestic regulations. The objective of this study is to demonstrate the safety of a shipping capsule for 192Ir special form radioisotope which produceed in the HANARO. The safety tests were carried out for the impact, percussion, bending and heat test conditions. And leakage tests were carried out before and after the each test. Also, the safety analyses were performed using computer codes in order to verify the test results. The capsule showed slight scratches and deformation, and maintained its structural and thermal integrities in all tests without any severe damage or melting. It also met the allowable limits of leakage rate after earth test. Therefore, it has been verified that the capsule was designed and fabricated to meet all requirements for the special form.
최영호,서홍주,임영혁,김정중,박성강,이석기,임진수,김은규 조선대학교 2001 The Medical Journal of Chosun University Vol.26 No.2
Pulmonary blastoma is a very rare primary neoplasm of the lung. We experienced a case of pulmonary blastoma in a 40 years old man. The mediobasal segmentectomy of the right lower lobe was performed. The patient was discharge on the postoperative days 6. There is no evidence of recurrence or metastasis on followup study during 7 months period after operation.
비만환자에서 발견된 난소의 Steroid Cell Tumor 1 예
서성석 ( Seo Seong Seog ),이정필 ( Lee Jeong Pil ),주희재 ( Ju Hui Jae ),이은주 ( Lee Eun Ju ),김호빈 ( Kim Ho Bin ),장기홍 ( Jang Gi Hong ),유희석 ( Yu Hui Seog ) 대한산부인과학회 2004 Obstetrics & Gynecology Science Vol.47 No.5
Ovarian steroid cell tumors are composed exclusively of cells that have the histologic features of steroid hormone secreting cells. And these are rare lesions and have been divided into four subtyes according to their size, location in the ovary, and presence or absence of crystals of Reinke in the cytoplasm as follows: stromal luteomas, hilus cell tumors, Leydig cell tumors (non-hilar type), and steroid cell tumors not otherwise specified. Steroid cell tumors often secret androgens, and manifest themselves with symptoms of virilization. Other presenting manifestations include hirsutism, amenorrhea, obesity, hypertension and alopecia. We experienced a case of ovarian steroid cell tumor, manifested by obesity and amenorrhea and present with a brief review of the literature.
Metabolic Syndrome Is an Independent Risk Factor for Acquired Premature Ejaculation
Seong Uk Jeh,Sol Yoon,Jae Hwi Choi,Jungmo Do,Deok Ha Seo,Sin Woo Lee,See Min Choi,Chunwoo Lee,Sung Chul Kam,Jeong Seok Hwa,Ky Hyun Chung,Ho Won Kang,Jae Seog Hyun 대한남성과학회 2019 The World Journal of Men's Health Vol.37 No.2
Purpose: To determine the role of metabolic syndrome (MetS) as a risk factor for acquired premature ejaculation (PE) after considering the various risk factors, such as lower urinary tract symptoms, erectile dysfunction, hypogonadism, and prostatitis. Materials and Methods: From January 2012 to January 2017, records of 1,029 men were analyzed. We performed multivari-ate analysis to identify risk factors for PE, including the covariate of age, marital status, International Prostate Symptom Score, International Index of Erectile Function (IIEF) score, National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) score, serum testosterone levels, and all components of MetS. Acquired PE was defined as self-reported intravaginal ejacula-tion latency time ≤3 minutes, and MetS was diagnosed using the modified National Cholesterol Education Program Adult Treatment Panel III criteria. Results: Of 1,029 men, 74 subjects (7.2%) had acquired PE and 111 (10.8%) had MetS. Multivariate analysis showed that the IIEF overall satisfaction score (odds ratio [OR]=0.67, p<0.001), NIH-CPSI pain score (OR=1.07, p=0.035), NIH-CPSI voiding score (OR=1.17, p=0.032), and presence of MetS (OR=2.20, p=0.022) were significantly correlated with the prevalence of acquired PE. In addition, the Male Sexual Health Questionnaire for Ejaculatory Dysfunction scores and ejaculation anxiety scores progressively decreased as the number of components of MetS increased. Conclusions: MetS may be an independent predisposing factor for the development of acquired PE. Effective prevention and treatment of MetS could also be important for the prevention and treatment of acquired PE.
진행성 비소세포폐암에 대한 2차 화학요법으로 paclitaxel과 cisplatin의 제 2상 임상연구
서영태,김봉석,고지영,최동석,최성호,김혜진,안영미,노용호,이경희 영남대학교 의과대학 2004 Yeungnam University Journal of Medicine Vol.21 No.2
gemcitabine과 carboplatin으로 치료받은 경력이 있는 진행성 비소세포폐암 환자 25명을 대상으로 2차 화학요법으로 paclitaxel과 cisplatin을 사용하여 다음과 같은 결과를 확인하였다. 전체 25명 중 5명에서 부분반응이 관찰되었으며, 반응군의 반응지속기간은 2~11개월로 중앙값 4.3개월이었다. 전체 환자의 무진행생존기간은 0~11개월로 중앙값 3.3개월이었으며, 생존기간은 1.3~39개월로 중앙값 7.4개월이었다. 전체 83회의 화학요법 중 WHO 3도의 혈소판감소증이 1회에서만 관찰되었으며, 비혈액학적 부작용도 감내할 만 하였다. 이상의 결과, paclitaxel과 cisplatin 복합화학요법은 진행성 비소세포폐암 환자에서 2차 요법으로 사용하였을 때 부작용이 적으며 효과적인 치료법의 하나로 판단된다. Background: To evaluate the efficacy and safety of paclitaxel and cisplatin against advanced non-small cell lung cancer (NSCLC) as a second-line chemotherapy. Subjects and Methods: Twenty-five patients were enrolled. The patients received 200 mg/㎡ paclitaxel as a 3-hour intravenous infusion and 60 mg/㎡ cisplatin as 30-minute intravenous infusion with vigorous hydration on day 1 every 28 days. The response was assessed every 2 cycles. Results: All 25 patients were assessed for their response and toxicity. Partial responses were observed in 5 patients. The overall response rate was 20%(95% confidence interval, 4%~36%) and the median response duration was 4.5(range, 2-11) months. The median time to progression was 3.3(range, 0-14) months. The median overall survival of all patients was 7.4(range, 1.3-39) months. The hematologic toxicities were minor and easily controlled. Conclusion: The combination chemotherapy of paclitaxel and cisplatin as a second-line treatment has a moderate efficacy with an acceptable toxicity in patients with advanced NSCLC.
Osteogenic Effects on Athymic Rat Calvarial Defects by Human Originated Cortical Bone
( Seog Jin Seo ),( Jae Won Heo ),( Ji Hwa Chae ),( Seong Hyun Jeon ),( Jin Kim ),( Nak Heon Kang ),( Kwang Won Lee ),( Ke Won Kang ) 한국조직공학·재생의학회 2009 조직공학과 재생의학 Vol.6 No.1
The purpose of this study was to evaluate effects of bone regeneration by the external sources of human bone substitutes which were developed for the transplantation. There are many different forms of bone based substitute materials. This study is focused on transplantable bone products developed by HansBiomed Inc. and some selected products, namely, human cortical bone powder, demineralized bone matrix(DBM), and bovine bone powders. SureOss and SureFuse are freeze-dried form of human cortical bone powder and DBM combined products, available from HansBiomed Corp, Korea, and Bio-Oss is the granule form of bovine bone powder by Geistlich- Pharma, Switzerland. The 4-mm critical size skull defects in athymic rats were prepared, and the defects were filled with the materials to be tested. The animals were sacrificed at 12 weeks. New bone formation was assessed by optical, radiographic and histological analyses. In our results, photographical density showed that SureOss-graft model induced the best bone formation occurring from defect edges. In summary, our findings indicate that human cortical bone powder enhances bone formation in rat model and the new products based human cortical bone powder may be a good bone substitute material for allografts.